A trial fibrillation (AF) is the most common sustained arrhythmia and is associated with significant morbidity, mortality, and cost (1,2).
properties of the atrium. Uncontrolled hypertension can result in several changes to the left atrial substrate including effects on ion channel function and increased atrial fibrosis ( Figure 1 ) (5-7).
Despite advancements in ablation technologies over the past decade, including contact force technology and the second-generation cryoballoon, the recurrence rate of AF after catheter ablation remains high (8) (9) (10) . These observations have led those of us who treat AF to examine other contributors to AF, with the realization that ablation alone may be insufficient to result in optimal arrhythmia control in patients. Hypertension is an obvious target given that is the most prevalent and potentially modifiable risk factor for AF (11, 12) . Multiple animal and clinical human studies have found a direct relationship between the risk of AF and systolic and diastolic blood pressure (13) (14) (15) (16) (17) (18) (19) (20) . This study is certainly compelling in advancing the notion that blood pressure control is indeed exquisitely linked to recurrence of AF after catheter ablation. There are, however, important caveats to this study that prevent this trial from being definitive.
The lack of randomization is an obvious limitation of 
